Related Experiment Video
Updated: Dec 9, 2025
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth
Haley Smalley1, Jennifer M Rowe1, Fernando Nieto1
1Division of Biology, Kansas State University, Manhattan, KS, 66506, USA.
Abstract:
Melanoma, a form of skin cancer, is one of the most common cancers in young men and women. Tumors require angiogenesis to provide oxygen and nutrients for growth. Pro-angiogenic molecules such as VEGF and anti-angiogenic molecules such as sFlt-1 control angiogenesis. In addition, the serum protein, Beta2 Glycoprotein I (β2-GPI) induces or inhibits angiogenesis depending on conformation and concentration. β2-GPI binds to proteins and negatively charged phospholipids on hypoxic endothelial cells present in the tumor microenvironment. We hypothesized that peptides derived from the binding domain of β2-GPI would regulate angiogenesis and melanoma growth. In vitro analyses determined the peptides reduced endothelial cell migration and sFlt-1 secretion. In a syngeneic, immunocompetent mouse melanoma model, β2-GPI-derived peptides also reduced melanoma growth in a dose-dependent response with increased sFlt-1 and attenuated vascular markers compared to negative controls. Importantly, administration of peptide with sFlt-1 antibody resulted in tumor growth. These data demonstrate the therapeutic potential of novel β2-GPI-derived peptides to attenuate tumor growth and endothelial migration is sFlt-1 dependent.
Insights
Novel peptides derived from Beta2 Glycoprotein I (β2-GPI) show promise in inhibiting melanoma growth by reducing angiogenesis. These findings suggest a new therapeutic strategy for skin cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Melanoma, a common skin cancer, relies on angiogenesis for tumor growth.
- Angiogenesis is regulated by pro-angiogenic (e.g., VEGF) and anti-angiogenic factors.
- Beta2 Glycoprotein I (β2-GPI) influences angiogenesis based on its conformation and concentration.
Purpose of the Study:
- To investigate the therapeutic potential of β2-GPI-derived peptides in regulating angiogenesis and melanoma growth.
- To determine if these peptides could serve as novel anti-melanoma agents.
Main Methods:
- In vitro studies on endothelial cell migration and sFlt-1 secretion.
- In vivo experiments using a syngeneic mouse melanoma model.
- Analysis of tumor growth, vascular markers, and sFlt-1 levels.
Main Results:
- β2-GPI-derived peptides reduced endothelial cell migration and sFlt-1 secretion in vitro.
- In vivo, peptides dose-dependently reduced melanoma growth, increased sFlt-1, and attenuated vascular markers.
- Co-administration with sFlt-1 antibody reversed the anti-tumor effect, indicating sFlt-1 dependence.
Conclusions:
- Novel β2-GPI-derived peptides effectively attenuate melanoma growth and endothelial migration.
- The anti-angiogenic effect of these peptides is mediated through an sFlt-1-dependent mechanism.
- These peptides represent a promising therapeutic strategy for melanoma treatment.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
